secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009253
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports Q1 2023 net loss of $34.3M; cash runway into H1 2025
------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $167.8M as of March 31, 2023, down from $267.1M a year ago; expected to fund operations into first half 2025.
- Net loss $34.3M ($0.63 per share) for Q1 2023, compared to $42.8M ($0.79 per share) in Q1 2022.
- R&D expenses $16.8M, down from $26.2M YoY; G&A expenses $19.0M, up from $15.1M due to non-recurring Catalent amendment costs.
- On track to report interim clinical data for PBGM01 (GM1 gangliosidosis) and PBFT02 (FTD) in 2023; protocol amendment submitted for higher dose of PBGM01.
- Initiated fourth global trial site for upliFT-D trial; expect to dose first patient at Dose 3 in second half 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/0001558370-23-009253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/pasg-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer